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Introduction
Adenomyosis is an important cause of menorrhagia and
dysmenorrhea. It has an elusive etiology that is charac-
terized by the presence of endometrial glands and
stroma located deep within the myometrium [1]. Al-
though the diagnosis is often made after hysterectomy,
transvaginal sonography and magnetic resonance imag-
ing have recently proven to be useful noninvasive tech-
niques for the preoperative diagnosis of adenomyosis
[2,3]. The effects of medical treatments are usually
restricted to the duration of therapy, which are associ-
ated with obvious side-effects and poor compliance.
Endometrial resection or ablation can improve the symp-
toms of menorrhagia but often fails to relieve dysmen-
orrhea. Hysterectomy is, therefore, usually the ultimate
therapeutic procedure for these patients. However, it is
unsuitable for women who desire to retain their fertility.
The levonorgestrel-releasing intrauterine system
(IUS), Mirena, has been approved in Europe for contra-
ception since 1990. Because of the suppressive effect of
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levonorgestrel on the endometrium, Mirena has also
been proven to be effective for the management of men-
orrhagia and dysmenorrhea [4], and as a progestin com-
ponent in postmenopausal hormone therapy [5]. It was
introduced in Taiwan in 1995 as an alternative therapy for
idiopathic menorrhagia [6]. Many cases of menorrhagia
are caused by adenomyosis, and Mirena was, therefore,
introduced for the treatment of adenomyosis in Taiwan
in 2000. Although it has been shown to be effective in
decreasing menstrual flow and relieving dysmenorrhea
as reported in other studies [7,8], insertion problems
and IUS expulsion were experienced more often among
those with severe adenomyosis.
Because adenomyosis is usually associated with an
enlarged uterus, uterine distortion or great retroflexed/
anteflexed uterine curvature, Mirena is commonly posi-
tioned incorrectly in these patients and can be easily
flushed out by the heavy menstrual flow [9]. In addi-
tion, low positioning or partial expulsion of Mirena may
be related to a longer period of spotting and bleeding.
We introduced a new insertion technique called Yang’s
method in 2001, to ensure accurate insertion and
optimal positioning of Mirena in women with severe
adenomyosis. This report provides a short description
of this novel method and our experience of using this
technique in women with adenomyosis.
Materials and Methods
Sample selection
A total of 273 women aged 24–52 years who attended
the National Taiwan University Hospital between
January 2001 and June 2008 with symptoms of adeno-
myosis-associated menorrhagia and/or dysmenorrhea
were included in the study. They underwent either trans-
vaginal sonography or magnetic resonance imaging for
the diagnosis of adenomyosis, and were then fitted with
Mirena (Bayer Schering Pharma, Berlin, Germany) after
signing an informed consent form. Patients with ade-
nomyosis in combination with submucosal myoma or
suspected endometrial disorders, such as endometrial
polyps, endometrial hyperplasia or malignancies de-
tected in the imaging study, were excluded. Mirena was
inserted after menstruation had ended or the menstrual
flow had decreased. All the procedures were performed
at our outpatient clinics by experienced clinical staff. The
use of Mirena to treat hypermenorrhea was approved
by the institutional review board of National Taiwan
University Hospital.
The cases were divided into two groups, according
to the insertion method and the physician: Yang’s
method, performed by M.Y.W. and Y.S.Y., and the
conventional method using the standard insertion
technique, performed by other physicians.
Symptoms of hypermenorrhea and dysmenorrhea
Hypermenorrhea was reported by the patients them-
selves as the passage of blood clots or episodes of heavy
bleeding during their menstruation. The severity of dys-
menorrhea was determined using the visual analog scale
which was calibrated from 0 to 10, with 0 representing
no pain and 10 representing the highest possible level of
pain [10]. Higher scores reflected a greater severity of
menstrual cramps. Other demographic data (age, parity,
mode of delivery) were also collected. Yang’s insertion
procedure is shown schematically in the Figure and is
described below.
Insertion technique
Physicians wore sterile gloves and maintained sterile con-
ditions throughout the insertion procedure. After open-
ing the package of the device, both threads were pulled
and fixed tightly in the cleft at the end of the handle. The
outer plastic tube was disconnected from the handle by
firmly pulling and rotating it, and separating it from the
whole insertion kit. The remaining plunger attached to
the Mirena was placed in the sterile package. The sound-
ing probe was placed into the lumen of the plastic tube
and inserted into the fundus (Figure A). The outer plastic
insertion tube was then slid forward to the fundus, and
the inner sounding probe was withdrawn, with care
being taken to keep the outer tube in the correct position
within the uterine cavity (Figure B). The arms of the
Mirena were then pinched off (again being careful to
keep the outer tube in the correct position within the
uterine cavity), and it was reinserted into the outer tube,
followed by the plunger (Figure C). Care was taken to
align the loop holding the strings with the cup-like recep-
tacle at the top of the plunger, when reinserting the
plunger. Finally, the plunger was pushed forward until
the handle reached the outer tube, and slight pressure
was exerted to reconnect them. Lastly, the Mirena was
released while holding the inserter firmly in position and
pulling the slider all the way down, as per the instruc-
tions (Figure D).
Follow-up
The bleeding pattern, intensity of dysmenorrhea and
hemoglobin level were recorded before and 3–5 months
after insertion. If the insertion time was close to the next
period, the contraceptive pill, Diane-35 (Bayer Schering
Pharma), was administered to postpone menstruation
in both groups by at least 2 weeks. This aimed to prevent
heavy blood flow from flushing out the Mirena before the
endometrium had completely atrophied. Patients who
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experienced prolonged spotting (> 14 days) were given
Diane-35 (once or twice a day) for the first 6 months.
Bleeding control is important in Asian women, because
prolonged spotting is associated with poor compliance.
Any suspicion of expulsion, including abrupt increases
in menstrual flow or missing the IUS tail in a pelvic exami-
nation, was confirmed by ultrasound.
Statistical analysis
Values of qualitative variables, such as pain and hemo-
globin, were compared before and after Mirena treat-
ment using paired t tests. IUS loss was defined as
complete expulsion or partial expulsion into the cervix.
Pearson χ2 test was performed to compare the IUS loss
rates between these two groups. Values of p < 0.05 were
considered statistically significant.
Results
There were no significant differences in the demographic
data between the two groups (Table 1). The insertion
of Mirena was smooth in all cases, with no need for anes-
thesia. Thirty-seven of 146 cases (25.3%) who received
A B
C D
Figure. Yang’s method of Mirena insertion. (A) The sounding probe is put into the lumen of the plastic tube and inserted into
the fundus. (B) The outer plastic insertion tube is slid forward, and the inner sounding probe is withdrawn, leaving the outer
tube in the correct position in the uterine cavity. (C) The Mirena arms are picked up and put it into the tunnel of the outer
tube, followed by insertion of the plunger. (D) The plunger is pushed forward until the handle reaches the outer tube, then
slight pressure is exerted to reconnect them. With the inserter held firmly in position, the Mirena is released by pulling down
the slider all the way, as shown in the instructions.
Table 1. Baseline characteristics of 273 patients with adenomyosis*
Characteristic Group 1 (Standard method; n = 146) Group 2 (Yang’s method; n = 127) p
Age, mean ± SD (yr) 40.5 ± 6.9 41.1 ± 7.0 0.46
Parity, mean ± SD
NSD 1.1 ± 1.1 1.1 ± 1.0 0.81
C/S 0.5 ± 0.8 0.4 ± 0.8 0.63
Pre-insertion condition, mean ± SD
Dysmenorrhea (VAS)† 6.7 ± 2.1 7.0 ± 1.8 0.23
Hb (g/dL) 10.0 ± 2.5 10.5 ± 2.1 0.08
Post-insertion‡, n (%)
IUS expulsions 37 (25.3) 13 (10.2) 0.001
IUS removals§ 12 (8.2) 9 (7.1) 0.73
*Statistical analysis was performed using t tests for all items except intrauterine system loss; †visual analog scale was used to grade the severity of dysmenorrhea, as
described in the Methods; ‡Pearson c2 test was used to compare intrauterine system loss ratios; §patients requested premature Mirena removal because of compli-
cations (e.g. vaginal spotting, back pain, watery discharge), critical conditions (e.g. severe anemia) or for other reasons (e.g. wish for pregnancy). SD = standard
deviation; NSD = normal spontaneous delivery; C/S = cesarean section ; VAS = visual analog scale; Hb = hemoglobin; IUS = intrauterine system.
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the standard insertion method (Group 1) experienced
IUS expulsion at 1 month to 2 years, compared with only
13 of 127 cases (10.2%) who received Yang’s method
(Group 2) (p = 0.001 by χ2 test; Table 1). In addition,
12 patients in Group 1 (8.2%) and nine in Group 2 (7.1%;
p = 0.73) requested premature removal of Mirena pre-
maturely because of complications (e.g. vaginal spot-
ting, back pain, watery discharge), critical conditions
(e.g. severe anemia), or other reasons (e.g. wish for
pregnancy).
Dysmenorrhea symptoms were greatly improved in
both groups after Mirena insertion (visual analog scale:
Group 1, 6.7 vs. 1.7, p < 0.001; Group 2, 7.0 vs. 1.6, 
p < 0.001; by paired t tests; Table 2). Although some
cases lacked adequate hemoglobin data for compari-
son, both groups demonstrated significant improve-
ments in anemia after Mirena insertion (Group 1, 10.0
vs. 11.1 g/dL, p = 0.001; Group 2, 10.5 vs. 11.6 g/dL,
p = 0.003; by paired t tests; Table 2).
Discussion
Although Mirena has been reported to be highly effec-
tive for the treatment of menorrhagia and reducing
menstrual blood loss [4,11], its efficacy in treating
adenomyosis has seldom been reported. A previous
observational study noted that Mirena significantly
improved the symptoms of adenomyosis and increased
hemoglobin and serum ferritin levels [7]. A recent
Korean study demonstrated that Mirena was effective
in reducing uterine volume and uterine blood flow, and
in relieving the symptoms of adenomyosis for 2 years
[12]. Most patients in both groups in the current study
experienced pain relief and significantly increased hemo-
globin levels.
Problems with Mirena insertion are often encoun-
tered in routine clinical practice among patients with
adenomyosis; Mirena insertion was reported to be more
difficult and painful than insertion of the copper device
[13], possibly because of its more rigid and broader
insertion tube [14]. The uterine cavity of women with
adenomyosis is sometimes large and distorted by ante-
flexion or retroflexion. This abnormal anatomy may lead
to IUS placement in the lower uterine cavity. These fac-
tors may further hinder the insertion of Mirena and lead
to incorrect positioning, which is a risk factor for expul-
sion [15]. This could partially explain why Mirena has a
higher expulsion rate than copper devices (about 4–9%)
in therapy for menorrhagia [16].
We have reported a novel method for Mirena inser-
tion in patients with a uterus distorted by adenomyosis.
The technique differs from the conventional method in
the use of a sounding probe as a guide wire to intro-
duce the outer rigid plastic tube. The metal sounding
probe can be easily bent to fit various uterine shapes,
and provides an accurate route for reaching the fundus.
The guidance provided by this sounding probe allows
the outer tube to be easily slid forward along the sound-
ing probe and Mirena to be located in the correct fundal
position. This is particularly important, because the
correct fundal position can ensure uniform exposure of
the endometrium to levonorgestrel, maximize the effi-
cacy of the device, and prevent expulsion. A significantly
higher expulsion rate and prolonged vaginal spotting
were noted with a levonorgestrel-releasing intracervical
device situated in the cervical canal, compared with an
IUS in the uterine cavity [17].
Moreover, using the standard insertion method, the
insertion of the outer tube into the uterine cavity de-
pends on blind attempts, which increases the risk of
uterine perforation, especially in patients with a dis-
torted uterus. Furthermore, a difficult insertion may be
time consuming and cause significant pain, which may,
in turn, create a need for anesthesia and so reduce the
acceptability of the treatment. We believe that this novel
technique makes Mirena insertion easier and safer, irre-
spective of the uterine shape.
Yang’s insertion method provides a more reliable
technique to ensure the correct placement of Mirena in
Table 2. Comparison of symptoms pre- and post-Mirena insertion*
Pre-insertion, mean ± SD Post-insertion, mean ± SD p
Dysmenorrhea (VAS)† 6.9 ± 2.0 1.7 ± 1.6 < 0.001
Group 1 (Standard method) 6.7 ± 2.1 1.7 ± 1.6 < 0.001
Group 2 (Yang’s method) 7.0 ± 1.8 1.6 ± 1.5 < 0.001
Hb (g/dL)†‡ 10.1 ± 2.1 11.2 ± 2.3 < 0.001
Group 1 (Standard method) 10.0 ± 2.5 11.1 ± 2.2 0.001
Group 2 (Yang’s method) 10.5 ± 2.1 11.6 ± 2.3 0.003
*Data are shown as mean ± standard deviation; †statistical analysis was performed using paired t tests for comparing values before and after Mirena treatment;
‡some cases lacked paired hemoglobin data for comparison (58 cases left in Group 1; 59 cases left in Group 2). SD = standard deviation; VAS = visual analog
scale; Hb = hemoglobin.
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patients with conditions such as severe adenomyosis.
This affords homogenous release of hormone, prevents
expulsion, and diminishes the risk of unpleasant com-
plications. Although the cases in this study were not
randomized, the results, nevertheless, suggest that this
insertion method was suitable for overcoming the prob-
lems of device insertion in patients with severe adeno-
myosis and a distorted uterus. A randomized study with
longer follow-up is needed to allow more definite con-
clusions to be drawn. Consideration should also be
given to the difference in size between Mirena and that of
some uterine cavities in patients with adenomyosis; a
standard-sized Mirena IUS may not be optimal in
patients with heavy menstrual bleeding. It is possible that
a variety of sizes of IUS may be required in the future.
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